Method and device for treating and enlarging body lumens

Claim 2

An endovascular stent comprising: a tubular structure having an initial diameter, said structure being composed of a first material expandable from the initial diameter to an enlarged diameter; a delivery matrix including at least one filament which is interlaced with the tubular structure and expandable therewith from said initial diameter to said enlarged diameter; and a bioactive substance releasably contained within the filament of the delivery matrix, wherein the filament is composed of a second material which is porous and/or which will degrade over time in a vascular environment to release the bioactive substance.

Claim 3

The endovascular stent as in claim 1, wherein said tubular structure is composed of an elastic material, whereby the tubular structure may be constrained to said initial diameter and thereafter released to said enlarged diameter.

Claim 4

The endovascular stent as in claim 1, wherein said tubular structure is composed of a non-elastic material, whereby the tubular structure may be expanded from said initial diameter to said enlarged diameter.

Claim 5

The endovascular stent as in claim 1, wherein said tubular structure includes at least one helically wound strand, and wherein the filament of the delivery matrix is counter-woven with said helically wound strand.

Claim 6

The endovascular stent as in claim 1, wherein said tubular structure includes at least one helically wound strand, and wherein the filament of the delivery matrix is laminated over at least a portion of said helically wound strand.

Claim 7

The endovascular stent as in claim 1, wherein said tubular structure includes a perforated cylinder, and wherein the filament is interwoven through the perforations in said cylinder.

Claim 8

The endovascular stent as in claim 1, wherein the filament is composed of a material which is biodegradable within a physiologic environment whereby the bioactive substance is released as the filament erodes within a blood vessel.

Claim 9

The endovascular stent as in claim 7, wherein the filament material is composed of at least one polymer system selected from the group consisting of lactic acid/glycolic copolymer, carbophenoxy propane/sebacic acid, polycaprolactones, polyanhydride and poly ortho-esters.

Claim 10

The endovascular stent as in claim 1, wherein the filament is composed of a material which is substantially biodegradable within a physiologic environment and elutes bioactive substances.

Claim 11

The endovascular stent as in claim 9, wherein the material is composed of at least one polymer selected from the group consisting of silicone, ethylene-vinyl acetate copolymer, poly (vinylalcohol).

Claim 12

The endovascular stent as in claim 1, wherein the bioactive substance is selected from the group consisting of organic molecules, proteins, peptides, nucleotides, carbohydrates, polysaccharides, mucopolysaccharides, simple sugar, glycoaminoglycans and steroids.

Claim 13

The endovascular stent as in claim 1, wherein the first material is non-degradable in the vascular environment.

Claim 14

The endovascular stent as in claim 12, wherein the first material is selected from the group consisting of stainless steel, tantalum, gold, titanium, tungsten, platinum, polyether sulfone, polyamide, polycarbonate, polypropylene, high molecular weight polyethylene, and carbon fiber.

Claim 15

An endovascular stent comprising: a tubular structure having an initial diameter, said structure being composed of a metal and being expandable from an initial diameter to an enlarged diameter; a delivery matrix including at least one first filament and at least one second filament, which first and second filaments are composed of a polymeric material and interlaced with the tubular structure and expandable therewith from said initial diameter to said enlarged diameter; and a bioactive substance releasably contained within both the first and second filaments wherein at least one of the first and second filaments is composed of a polymer material which will degrade over time in a vascular environment to release the bioactive substance and wherein the first and second filaments are composed of different materials.

Claim 16

An endovascular stent comprising: a tubular structure having an initial diameter, said structure being composed of a metal and being expandable from an initial diameter to an enlarged diameter; a delivery matrix including at least one first filament and at least one second filament, which first and second filaments are composed of a polymeric material and interlaced with the tubular structure and expandable therewith from said initial diameter to said enlarged diameter; and a bioactive substance releasably contained within both the first and second filaments wherein at least one of the first and second filaments is composed of a polymer material which will degrade over time in a vascular environment to release the bioactive substance and wherein the first and second filaments are composed of different materials.

Claim 17

The endovascular stent as in claim 14, wherein the first filament is composed of a first material selected to degrade and release the bioactive substance over a first time period and wherein the second filament is composed of a second material selected to degrade and release the bioactive substance over a second time period.

Claim 18

The endovascular stent as in claim 14, wherein the at least one filament material is composed of a least one polymer selected from the group consisting of lactic acid/glycolic copolymer, carbophenox propane/sebacic acid, polycaprolactones, polyanhydride and poly ortho-esters.

Claim 19

The endovascular stent as in claim 16, wherein both the first and second filaments are composed of the at least one polymer.

Claim 20

The endovascular stent as in claim 14, wherein one of the first and second filaments is composed of a material which is substantially non-biodegradable within a vascular environment which elutes substances.

Claim 21

The endovascular stent as in claim 18, wherein the non-biodegradable material is composed of at least one polymer selected from the group consisting of ethylene-vinyl acetate copolymer, styrene-divinyl benzene copolymer, and methyl methacrylate-ethylene glycol copolymer.

Claim 24

The method as in claim 20, wherein the body lumen is a blood vessel and the selected location is a region of stenosis.

Claim 25

The method as in claim 21, wherein the bioactive substance is selected from the group consisting of organic molecules, proteins, peptides, nucleotides, carbohydrates, polysaccharides, mucopolysaccharides, simple sugar, glycoaminoglycans, and steroids.

Claim 26

The method as in claim 20, wherein the first material is non-degradable in the vascular environment.

Claim 27

The method as in claim 23, wherein the first material is non-degradable in the vascular environment.